Australia is recognised as a hub for early phase trials and many international biotech and pharmaceutical companies continue to launch early phase trials in Australia.

CTA has an established Phase I Group that comprises sites conducting the greatest number of Phase I cancer trials in Australia.

Coupled with other research collaborators within Phase I institutions, this unique clinical group includes key opinion leaders who can review pre-clinical trial data and quickly offer impartial recommendations regarding undertaking a clinical trial, including study design, strategy, submissions and budget.

CTA can facilitate the Expert Toxicology Review component required for First-Time-In-Human HREC submission. CTA completes this step in advance of submission to decrease HREC queries and significantly improve speed of HREC review and approval.

CTA is capable of facilitating Phase I trials across all tumour types, in tumour-specific or molecular-target-specific studies.

Contact Us to discuss your early phase clinical trial